CVS Health says it plans to split into two publicly traded companies by the first half of 2028, separating its pharmacy business, including roughly 9,000 retail locations, from its insurance business and the pharmacy benefit manager Caremark. The move comes more than two years after the company considered a breakup and walked away. This time, the case looks stronger, and the company says it is acting from strength rather than distress.
The strongest argument for the split is the change in the retail pharmacy business. According to the report, the unit has become more consistently profitable, and CVS has beaten Wall Street earnings estimates for eight consecutive quarters. CEO David Joyner said that two years ago the company was "in a turnaround" without the flexibility to execute a split. The report also notes that expected operating cash flow of at least $15.5 billion in 2026 is roughly 70% above the $9.1 billion reported for 2024. Those numbers make a separation far easier to defend than it was before.
The enthusiasm should be tempered, though. The report describes retail pharmacy margins of roughly 4% to 5%, which is thin, and it says analysts expect the unit to be valued at a discount. Investors reacted badly to the announcement, with shares falling about 12%. A company can be stable and still struggle to convince the market that its pieces are worth more apart than together. CVS was still promoting its integrated model at its investor day last year, which makes this reversal worth scrutiny.
The regulatory pressure on Caremark is another reason to watch closely. The report notes state laws in Tennessee and Arkansas that would bar one company from owning both a pharmacy and a PBM, and says the Arkansas measure has been held up in court. Joyner told the Wall Street Journal that regulation was not the reason for the split. That may be true, but it does not remove the question. Investors and customers deserve a clear account of how the businesses will continue to work together once they are separate.
My view is that the split should go ahead only if CVS can show that each company will serve patients and pharmacies better on its own. The company should publish the terms of the commercial relationship between the two businesses before the deal closes, so outside parties can judge whether the separation is about focus or about escaping scrutiny.